PDCD1 and skin squamous cell carcinoma: Overall, the safety profile of cemiplimab in advanced cSCC mirrors that of other PD-1 inhibitors but is characterized by a predominance of cutaneous, endocrine, hepatic, and pulmonary irAEs.